Investigators at the Sunnybrook Health Sciences Centre, University of Toronto initiated a study to assess the risk factors for metastases in patients on active surveillance.
About three percent of patients on surveillance had metastasis by a median of seven years after diagnosis. This risk increased to ten percent in patients with Gleason score (GS) 7.